Featured Research

from universities, journals, and other organizations

The Affordable Care Act: Translational research experiment to improve health

Date:
December 2, 2013
Source:
Tufts Clinical and Translational Science Institute
Summary:
An editorial published says the Patient Protection and Affordable Care Act is an example of the role of experimentation in improving health at the public policy level.

An editorial by Harry P. Selker, MD, MSPH, William H. Frist, MD, and Stuart Altman, PhD, published in the November 27 issue of Science Translational Medicine says the Patient Protection and Affordable Care Act (ACA) is an example of the role of experimentation in improving health at the public policy level.

The authors point out that while the ACA is an experiment, it is not radical. It builds on learning from previous experiments such as the establishment of Medicaid and, more recently, Massachusetts health care reform. It also uses extant structures by being built upon existing private insurance providers. As the rollout of the ACA continues, like any good experiment, there are mechanisms for adjustments that should improve the overall outcome.

The authors encourage scientists and clinicians to help the public to better understand the ACA by likening it to traditional biomedical research: it follows tested approaches used in all clinical and translational research, and we stand to learn a great deal from it about ways to advance health care and wellness in the United States.


Story Source:

The above story is based on materials provided by Tufts Clinical and Translational Science Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. H. P. Selker, W. H. Frist, S. H. Altman. The Affordable Care Act as Translational Research. Science Translational Medicine, 2013; 5 (213): 213ed20 DOI: 10.1126/scitranslmed.3007994

Cite This Page:

Tufts Clinical and Translational Science Institute. "The Affordable Care Act: Translational research experiment to improve health." ScienceDaily. ScienceDaily, 2 December 2013. <www.sciencedaily.com/releases/2013/12/131202082652.htm>.
Tufts Clinical and Translational Science Institute. (2013, December 2). The Affordable Care Act: Translational research experiment to improve health. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/12/131202082652.htm
Tufts Clinical and Translational Science Institute. "The Affordable Care Act: Translational research experiment to improve health." ScienceDaily. www.sciencedaily.com/releases/2013/12/131202082652.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins